文献速递心脑血管急症重症综合管理与镇静镇痛

持续输注高渗盐水与标准治疗对创伤性脑损伤患者6个月神经功能结局的影响:COBI随机临床试验

Effect of Continuous Infusion of Hypertonic Saline vs Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic Brain Injury: The COBI Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论中重度创伤性脑损伤患者持续输注20%高渗盐水与单纯标准治疗相比,6个月GOS-E评分无显著差异(校正共同OR 1.02,95%CI 0.71-1.47;P=0.92)。

COBI多中心随机临床试验在法国9个ICU纳入370例中重度创伤性脑损伤患者,随机分为持续输注20%高渗盐水+标准治疗组(n=185)或单纯标准治疗组(n=185),高渗盐水输注48小时,若仍存在颅内高压风险则延长。主要终点6个月GOS-E评分经盲法集中评估,校正预设预后因素后共同OR为1.02(95%CI 0.71-1.47;P=0.92),无显著差异。12项次要结局中10项无显著差异;颅内高压发生率干预组33.7% vs 对照组36.3%(绝对差-2.6%,95%CI -12.3%至7.2%;OR 0.80,95%CI 0.51-1.26),6个月死亡率干预组15.9% vs 对照组20.8%(绝对差-4.9%,95%CI -12.8%至3.1%;HR 0.79,95%CI 0.48-1.28)。作者结论认为持续输注20%高渗盐水未显著改善6个月神经功能,但置信区间宽,研究检测临床重要差异的效能可能有限。

要点

  • 中重度创伤性脑损伤患者持续输注20%高渗盐水+标准治疗与单纯标准治疗相比,6个月GOS-E评分无显著差异(校正共同OR 1.02,95%CI 0.71-1.47;P=0.92)。
  • 颅内高压发生率干预组33.7% vs 对照组36.3%(绝对差-2.6%,95%CI -12.3%至7.2%;OR 0.80,95%CI 0.51-1.26),无显著差异。
  • 6个月死亡率干预组15.9% vs 对照组20.8%(绝对差-4.9%,95%CI -12.8%至3.1%;HR 0.79,95%CI 0.48-1.28),无显著差异。
  • 12项次要结局中10项无显著差异。
  • 作者指出置信区间宽,研究检测临床重要差异的效能可能有限。

适用人群与场景

  • 法国9个ICU纳入的中重度创伤性脑损伤成人患者,2017年10月至2019年8月招募,共370例(中位年龄44岁,四分位距27-59岁;女性77例,占20.2%)。

处置流程与药物剂量

  • 干预组:持续输注20%高渗盐水+标准治疗,输注48小时,若患者仍存在颅内高压风险则延长输注时间。
  • 对照组:单纯标准治疗。

研究设计与关键结果

  • 多中心随机临床试验,370例中重度创伤性脑损伤患者随机分为持续输注20%高渗盐水+标准治疗组(n=185)或单纯标准治疗组(n=185),359例(97%)完成试验。
  • 主要终点6个月GOS-E评分(范围1-8,评分越低功能结局越差)由盲法评估者集中获取,校正预设预后因素后共同OR为1.02(95%CI 0.71-1.47;P=0.92),OR>1.0 favoring干预。
  • 12项次要结局中10项无显著差异;颅内高压发生率干预组33.7%(62例)vs 对照组36.3%(66例),绝对差-2.6%(95%CI -12.3%至7.2%),OR 0.80(95%CI 0.51-1.26)。
  • 6个月死亡率干预组15.9%(29例)vs 对照组20.8%(37例),绝对差-4.9%(95%CI -12.8%至3.1%),HR 0.79(95%CI 0.48-1.28)。

证据类型、等级与局限

  • 证据类型:多中心随机临床试验(RCT)。
  • 局限:原文报告置信区间宽,研究检测临床重要差异的效能可能有限。

对床旁实践的改变

  • 作者结论认为,在中重度创伤性脑损伤患者中,与标准治疗相比,持续输注20%高渗盐水未显著改善6个月神经功能状态;但置信区间宽,研究检测临床重要差异的效能可能有限。

指南或共识出处

  • COBI随机临床试验(ClinicalTrials.gov Identifier: NCT03143751)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Fluid therapy is an important component of care for patients with traumatic brain injury, but whether it modulates clinical outcomes remains unclear.

OBJECTIVE: To determine whether continuous infusion of hypertonic saline solution improves neurological outcome at 6 months in patients with traumatic brain injury.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial conducted in 9 intensive care units in France, including 370 patients with moderate to severe traumatic brain injury who were recruited from October 2017 to August 2019. Follow-up was completed in February 2020.

INTERVENTIONS: Adult patients with moderate to severe traumatic brain injury were randomly assigned to receive continuous infusion of 20% hypertonic saline solution plus standard care (n = 185) or standard care alone (controls; n = 185). The 20% hypertonic saline solution was administered for 48 hours or longer if patients remained at risk of intracranial hypertension.

MAIN OUTCOMES AND MEASURES: The primary outcome was Extended Glasgow Outcome Scale (GOS-E) score (range, 1-8, with lower scores indicating worse functional outcome) at 6 months, obtained centrally by blinded assessors and analyzed with ordinal logistic regression adjusted for prespecified prognostic factors (with a common odds ratio [OR] >1.0 favoring intervention). There were 12 secondary outcomes measured at multiple time points, including development of intracranial hypertension and 6-month mortality.

RESULTS: Among 370 patients who were randomized (median age, 44 [interquartile range, 27-59] years; 77 [20.2%] women), 359 (97%) completed the trial. The adjusted common OR for the GOS-E score at 6 months was 1.02 (95% CI, 0.71-1.47; P = .92). Of the 12 secondary outcomes, 10 were not significantly different. Intracranial hypertension developed in 62 (33.7%) patients in the intervention group and 66 (36.3%) patients in the control group (absolute difference, -2.6% [95% CI, -12.3% to 7.2%]; OR, 0.80 [95% CI, 0.51-1.26]). There was no significant difference in 6-month mortality (29 [15.9%] in the intervention group vs 37 [20.8%] in the control group; absolute difference, -4.9% [95% CI, -12.8% to 3.1%]; hazard ratio, 0.79 [95% CI, 0.48-1.28]).

CONCLUSIONS AND RELEVANCE: Among patients with moderate to severe traumatic brain injury, treatment with continuous infusion of 20% hypertonic saline compared with standard care did not result in a significantly better neurological status at 6 months. However, confidence intervals for the findings were wide, and the study may have had limited power to detect a clinically important difference.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03143751.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Roquilly A, Moyer JD, Huet O, et al. Effect of Continuous Infusion of Hypertonic Saline vs Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic Brain Injury: The COBI Randomized Clinical Trial. JAMA. 2021. PMID: 34032829. doi:10.1001/jama.2021.5561

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。